|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases显示文摘AIM:To evaluate the utility of serum and urine metabolomic analysis in diagnosing and monitoring of inflammatory bowel diseases(IBD).METHODS:Serum and urine samples were collected from 24 patients with ulcerative colitis(UC),19 patients with the Crohn’s disease(CD)and 17 healthy controls.The activity of UC was assessed with the Simple Clinical Colitis Activity Index,while the activity of CD was determined using the Harvey-Bradshaw Index.The analysis of serum and urine samples was performed using proton nuclear magnetic resonance(NMR)spectroscopy.All spectra were exported to Matlab for preprocessing which resulted in two data matrixes for serum and urine.Prior to the chemometric analysis,both data sets were unit variance scaled.The differences in metabolite fingerprints were assessed using partial least-squaresdiscriminant analysis(PLS-DA).Receiver operating characteristic curves and area under curves were used to evaluate the quality and prediction performance of the obtained PLS-DA models.Metabolites responsible for separation in models were tested using STATISTICA10 with the Mann-Whitney-Wilcoxon test and the Student’s t test(α=0.05).RESULTS:The comparison between the group of patients with active IBD and the group with IBD in remission provided good PLS-DA models(P value 0.002for serum and 0.003 for urine).The metabolites that allowed to distinguish these groups were:N-acetylated compounds and phenylalanine(up-regulated in serum),low-density lipoproteins and very low-density lipoproteins(decreased in serum)as well as glycine(increased in urine)and acetoacetate(decreased in urine).The significant differences in metabolomic profiles were also found between the group of patients with active IBD and healthy control subjects providing the PLS-DA models with a very good separation(P value<0.001 for serum and 0.003 for urine).The metabolites that were found to be the strongest biomarkers included in this case:leucine,isoleucine,3-hydroxybutyric acid,N-acetylated compounds,acetoacetate,glycine,phenylalanine and lactate(increased in serum),creatine,dimethyl sulfone,histidine,choline and its derivatives(decreased in serum),as well as citrate,hippurate,trigonelline,taurine,succinate and 2-hydroxyisobutyrate(decreased in urine).No clear separation in PLS-DA models was found between CD and UC patients based on the analysis of serum and urine samples,although one metabolite(formate)in univariate statistical analysis was significantly lower in serum of patients with active CD,and two metabolites(alanine and N-acetylated compounds)were significantly higher in serum of patients with CD when comparing jointly patients in the remission and active phase of the diseases.Contrary to the results obtained from the serum samples,the analysis of urine samples allowed to distinguish patients with IBD in remission from healthy control subjects.The metabolites of importance included in this case up-regulated acetoacetate and down-regulated citrate,hippurate,taurine,succinate,glycine,alanine and formate.CONCLUSION:NMR-based metabolomic fingerprinting of serum and urine has the potential to be a useful tool in distinguishing patients with active IBD from those in remission. | Tomasz Dawiskiba Stanislaw Deja Agata Mulak Adam Zabek Ewa Jawień Dorota Pawelka Miroslaw Banasik Agnieszka Mastalerz-Migas Waldemar Balcerzak Krzysztof Kaliszewski Jan Skóra Piotr Bar Krzysztof Korta Kornel Pormańczuk Przemyslaw Szyber Adam Litarski Piotr Mlynarz | 2014 | World Journal of Gastroenterology2014，20，1： | 15 |
| 2 | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised phase 3 MRC COIN trial显示文摘 | Maughan TS Adams RA Smith CG | 2011 | Lancet2011，377，9783： | 1 |
| 3 | Semiconstrained arthroplasty for the treat- ment of rheumatoid arthritis of the elbow 显示文摘 | Morrey BF Adams RA | 1992 | J Bone Joint Surg (Am)1992，74，4： | 1 |
| 4 | Low recognition of childhood overweight and disease risk among Native-American earegivers 显示文摘 | Adams AK Quinn RA Prince RJ | 2005 | Obes Res2005，13，： | 1 |
| 5 | Semiconstrained arthroplasty for the treatment of rheumatoid arthritis of the elbow显示文摘 | Morrey BF Adams RA | 1992 | Journal of Bone&Joint Surgery1992，74，74： | 1 |
| 6 | Semicontrained elbow replacement for distal humeral nonunion显示文摘 | Morrey BF Adams RA | 1995 | J Bone Joint Surg (Br)1995，77，： | 1 |
| 7 | Semiconstrained arthroplasty for the treat-ment of rheumatoid arthritis of the elbow 显示文摘 | Morrey BF Adams RA | 1992 | J Bone Joint Surg(Am)1992，74，4： | 1 |
| 8 | Semiconstrained arthroplasty for the treatment of rheumatoid arthritis of the elbow显示文摘 | Morrey BF Adams RA | 1992 | J Bone Joint Surg Am1992，74，4： | 1 |
| 9 | Intermittent versus con- tinuous oxaliplatin and fluorepyrimidine combination chemotherapy for first - line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC trial 显示文摘 | Adams RA Meade AM Seymour MT | 2011 | Lancet Oncol2011，12，7： | 1 |
| 10 | 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC) :a randomised superiority trial ( MRC COIN ) 显示文摘 | Maughan T Adams RA Smith CG | 2009 | EJC Suppl2009，7，3： | 1 |
| 11 | Rheological and function of blood cells in stored bank blood and salvaged blood显示文摘 | Kirkpatrick U J Adams RA Lardi A | 1998 | Br J haematol1998，101，2： | 1 |
| 12 | Semiconstrained arthroplasty for the treatment of rheumatoid arthristis of the elbow显示文摘 | Mooey BF Adams RA | 1992 | J Bone Joint Surg(Am)1992，74，： | 1 |
| 13 | The sequence of the human genome显示文摘 | Venter JC Adams MD Myers EW Li PW Mural R J Sutton GG Smith HO Yandell M Evans CA Holt RA | | 0，，： | 1 |
| 14 | Addition of cetuximab to ox- aliplatin-based first-line combination chemotherapy for treatment of advanced eolorectal cancer: results of the randnmised phase 3 MRC COIN trial显示文摘 | Maughan TS Adams RA Smith CG | 2011 | Lancet2011，377，9783： | 1 |
| 15 | Toxicity associat- ed with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the Mrc conin trial experi- ence显示文摘 | Adams RA Meade AM Madi A | 2009 | Br J Cancer2009，100，2： | 1 |
| 16 | Semiconstrained arthroplasty for the treatment of rheumatoid arthritis of the elbow显示文摘 | Morrey BF Adams RA | 1992 | J Bone Joint Surg Am1992，74，4： | 1 |
| 17 | Complications and mortal-it)' associated with bilateral or unilateral total knee arthroplasty显示文摘 | Moirey BF Adams RA llstrup DM | 1987 | JBone Joint Surg(Am)1987，69，4： | 1 |
| 18 | Salvage of failed prior en-dovascular abdominal aortic aneurysm repair with fenestrated endo-vascular stent grafts显示文摘 | Adam DJ Fitridge RA Berce M | 2006 | J Vasc Surg2006，44，6： | 1 |
| 19 | Fibrin mechanisms and functions in nervous system pathology 显示文摘 | Adams RA Passino M Sachs BD | 2004 | Mol Interv2004，4，： | 1 |
| 20 | Complica- tions and mortality associated with bilateral or unilateral total knee arthrop lasty 显示文摘 | Morrey BF Adams RA Ilstrup DM | 1987 | J Bone Joint Surg ( Am)1987，69，48： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员